A previous study showed that enhanced CD44 expression correlated with shorter OS in ccRCC, thus considering it as an independent risk factor capable of predicting recurrence-free survival, disease-specific survival and OS in patients with ccRCC. This evidence concerns the gene CD44 and nonpapillary renal cell carcinoma.